KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Castle Biosciences (CSTL) Assets Average (2019 - 2025)

Castle Biosciences' Assets Average history spans 7 years, with the latest figure at $570.7 million for Q4 2025.

  • For Q4 2025, Assets Average rose 9.14% year-over-year to $570.7 million; the TTM value through Dec 2025 reached $570.7 million, up 9.14%, while the annual FY2025 figure was $554.9 million, 12.72% up from the prior year.
  • Assets Average for Q4 2025 was $570.7 million at Castle Biosciences, up from $553.8 million in the prior quarter.
  • Across five years, Assets Average topped out at $570.7 million in Q4 2025 and bottomed at $426.1 million in Q2 2023.
  • The 5-year median for Assets Average is $453.0 million (2022), against an average of $471.4 million.
  • The largest annual shift saw Assets Average surged 265.27% in 2021 before it fell 5.98% in 2023.
  • A 5-year view of Assets Average shows it stood at $448.1 million in 2021, then increased by 0.99% to $452.6 million in 2022, then dropped by 1.74% to $444.7 million in 2023, then rose by 17.59% to $522.9 million in 2024, then increased by 9.14% to $570.7 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Assets Average are $570.7 million (Q4 2025), $553.8 million (Q3 2025), and $523.2 million (Q2 2025).